慢性乙型肝炎合并代谢性疾病罹患肝细胞癌的风险分析

摘要/Abstract

摘要： 肝细胞癌是全球第五大常见肿瘤,发病率高且早期诊断率低,往往预后较差。慢性乙型肝炎是我国肝细胞癌发生的最重要病因,随着乙肝疫苗的广泛接种及抗乙肝病毒药物的应用,乙肝病毒感染相关肝癌有下降趋势。近年来,代谢性疾病逐渐成为肝细胞癌重要病因。该文对慢性乙型肝炎患者合并代谢相关性疾病罹患肝细胞癌的风险分析作一综述,以期为临床监测和早期干预肝细胞癌提供参考。

关键词: 肝细胞癌, 慢性乙型肝炎, 代谢性疾病, 代谢功能障碍相关脂肪性肝病

万明月, 王晓琳, 徐玉敏, 谢青. 慢性乙型肝炎合并代谢性疾病罹患肝细胞癌的风险分析[J]. 肝脏, 2023, 28(10): 1238-1241.

[1] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 394(10204): 1145-1158.
[2] Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2019,104(9):3939-3985.
[3] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver diseas: an international expert consensus statement. J Hepatol, 2020, 7(1): 202-209.
[4] Yu MW, Lin CL, Liu CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study. Gastroenterology, 2017, 153(4): 1006-1017.
[5] Huang J, Jing M, Wang C, et al. The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease:a population-based study. J Med Virol, 2020, 92(8): 1191-1197.
[6] Zhong GC, Wu YL, Hao FB, et al. Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population:a case-control study with propensity score analysis. J Viral Hepat, 2018, 25(7): 842-852.
[7] Yang MH, Sung J, Gwak GY, et al. The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J Clin Lipidol, 2016, 10(2): 289-298.
[8] Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology, 2008, 135(1): 111-121.
[9] Sohn W, Lee HW, Lee S, et al. Obesity and the risk of primary liver cancer: a systematic review and meta-analysis. Clin Mol Hepatol, 2021, 27(1): 157-174.
[10] Nderitu P, Bosco C, Garmo H, et al. The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort. Int J Cancer, 2017, 141(6): 1148-1160.
[11] Tan Y, Zhang X, Zhang W, et al. The influence of metabolic syndrome on the risk of hepatocellular carcinoma in patients with chronic hepatitis b infection in Mainland China. Cancer Epidemiol Biomarkers Prev, 2019, 28(12): 2038-2046.
[12] Tung HD, Wang JH, Tseng PL, et al. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol, 2010, 105(3): 624-631.
[13] Coman LI, Coman OA, B?d?r?u IA, et al. Association between liver cirrhosis and diabetes mellitus: a review on hepatic outcomes. J Clin Med, 2021, 10(2):262.
[14] Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398.
[15] Choi HSJ, Brouwer WP, Zanjir WNR, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology, 2020, 71(2): 539-548.
[16] Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 2018, 67(1): 123-133.
[17] Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep, 2021, 3(5): 100350.
[18] Choe JW, Hyun JJ, Kim B, et al. Influence of metabolic syndrome on cancer risk in HBV carriers: a nationwide population based study using the national health insurance service database. J Clin Med, 2021, 10(11):2401.
[19] Kim NH, Cho YK, Kim BI, et al. Effect of metabolic syndrome on the clinical outcomes of chronic hepatitis B patients with nucleos(t)ide analogues treatment. Dig Dis Sci, 2018, 63(10): 2792-2799.
[20] Hsiang JC, Wong GL, Chan HL, et al. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. Aliment Pharmacol Ther, 2014, 40(6): 716-726.
[21] Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol, 2019, 70(3): 361-370.
[22] Chettouh H, Lequoy M, Fartoux L, et al. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int, 2015, 35(10): 2203-2217.
[23] Ioannou GN. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metab, 2016, 27(2): 84-95.
[24] Goh MJ, Sinn DH, Kim S, et al. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology, 2020, 71(6): 2023-2032.
[25] Jarcuska P, Drazilova S, Fedacko J, et al. Association between hepatitis B and metabolic syndrome: current state of the art. World J Gastroenterol, 2016, 22(1): 155-164.
[26] Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology, 2010, 138(5): 1747-1754.
[27] Auth PA, da Silva GR, Amaral EC, et al. Croton urucurana Baill. Ameliorates metabolic associated fatty liver disease in rats. Front Pharmacol, 2022, 13: 886122.
[28] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol, 2019, 71(4): 793-801.

慢性乙型肝炎合并代谢性疾病罹患肝细胞癌的风险分析

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张会, 李晓琴, 王成伟, 王蔚, 肖丽, 咸建春. 关于将慢性乙型肝炎纤维化分期中“advanced fibrosis”译为“进展期肝纤维化”的商榷[J]. 肝脏, 2023, 28(9): 1011-1011.
[2]	刘百怡, 饶慧瑛. 非酒精性脂肪性肝病更名及其影响[J]. 肝脏, 2023, 28(9): 1012-1014.
[3]	钟剑秋, 徐燕, 徐敏. 抗病毒治疗慢性乙型肝炎患者血清外泌体HBV-miR-3动态变化与病毒学指标的关系[J]. 肝脏, 2023, 28(9): 1044-1047.
[4]	蒋兆荣, 邹梅, 姬腾飞, 刘欢, 顾生旺, 冯伟广, 赵文玺. 核苷(酸)类似物联合聚乙二醇干扰素治疗慢性乙型肝炎的临床疗效分析[J]. 肝脏, 2023, 28(9): 1048-1049.
[5]	顾达, 童聪, 王维钊, 向晓星, 赵祥安. 血清IL-10对慢性乙型肝炎患者抗病毒治疗后e抗原转阴的预测作用[J]. 肝脏, 2023, 28(9): 1053-1056.
[6]	殷琳琳, 吕慧, 王戊辰, 刘学进. 超声弹性成像检测肝脏、脾脏硬度值与血清肝纤维化指标对慢性乙型肝炎患者肝纤维化的评价[J]. 肝脏, 2023, 28(9): 1064-1067.
[7]	王凯骊, 胡晓炜, 殷剑, 刘庆阳, 王秋波. 血清中期因子水平对肝细胞癌患者TACE治疗反应的诊断和评估[J]. 肝脏, 2023, 28(9): 1072-1074.
[8]	葛舒, 刘洋洋. 超声造影与增强CT对肝内胆管癌与肝细胞癌的鉴别价值[J]. 肝脏, 2023, 28(9): 1075-1078.
[9]	张翔, 李莹莹, 汤青, 李伟, 孙立柱. CD8⁺ T淋巴细胞水平对晚期肝细胞癌患者免疫治疗疗效的评估价值[J]. 肝脏, 2023, 28(9): 1084-1087.
[10]	彭国庆, 王小梅, 王瑞, 余欢, 王思涵. 术前炎症标志物评估肝细胞癌手术预后价值的研究进展[J]. 肝脏, 2023, 28(9): 1123-1126.
[11]	孙鸿展, 王欣茹, 肖丽, 薛荣荣, 咸建春. 《慢性乙型肝炎防治指南(2022年版)》及解读等两个问题的讨论[J]. 肝脏, 2023, 28(8): 885-886.
[12]	梁红妍, 申笙, 孙剑. 靶向cccDNA以实现慢性乙型肝炎治愈[J]. 肝脏, 2023, 28(8): 887-888.
[13]	张家齐, 王再超, 杨家耀, 王晓梦, 赵玉. 慢性乙型肝炎肝硬化患者继发肝性脑病风险预测模型的构建与验证[J]. 肝脏, 2023, 28(8): 916-920.
[14]	聂彬, 赵铁军, 张胜龙. 肝细胞癌伴微血管侵犯不同切缘方案下根治术的预后分析[J]. 肝脏, 2023, 28(8): 921-923.
[15]	徐嘉嫔, 邵春燕, 刘地发, 许亚春. 体素内不相干运动扩散加权成像对肝细胞癌微血管侵犯预测和TACE疗效的评估价值[J]. 肝脏, 2023, 28(8): 938-942.